Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02690324
Other study ID # 2015-07-151
Secondary ID
Status Recruiting
Phase N/A
First received February 11, 2016
Last updated February 18, 2016
Start date November 2015

Study information

Verified date November 2015
Source Samsung Medical Center
Contact Hong Jin Jeon, MD
Phone 82-10-3198-9586
Email jhj001001@gmail.com
Is FDA regulated No
Health authority South Korea: Institutional Review Board
Study type Interventional

Clinical Trial Summary

development of skin adhesive patches for the monitoring and prediction of mental disorders


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date
Est. primary completion date February 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 20 Years and older
Eligibility Inclusion Criteria:

- the existence of a current Major depressive disorder or panic disorder during the screening and baseline visits, per the Mini-International Neuropsychiatric Interview (Sheehan et al., 1998) according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)

- scored at least 16 on the HDRS-17 (Hamilton, 1960) for MDD and 7 on the Panic disorder severity scale for panic disorder patients at the baseline visits.

Exclusion Criteria:

- Patients who had psychotic disorder (e.g., schizophrenia or delusional disorder), bipolar affective disorder,active alcohol or drug use disorder, neurological illness including significant cognitive impairment or Parkinson's disease, mental retardation, significant medical conditions, epilepsy, histories of alcohol or drug dependence, personality disorders, or brain damages

- patients who were at serious risk for suicide of homicide

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Behavioral:
cognitive stress (serial 7)


Locations

Country Name City State
Korea, Republic of Samsung Medical Center Seoul Irwon-dong, Gangnam-gu

Sponsors (1)

Lead Sponsor Collaborator
Samsung Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Electrodermal activity(EDA) changes of skin conductane level(SCL) and skin conductance response(SCR) baseline, 0.5, 1,2,3 months No
Primary Heart rate variability changes of SDNN, RMSSD and LF/HF ratio baseline, 0.5, 1,2,3 months No
Secondary Brain-derived neurotrophic factor(BDNF) genotyping: Val66Met baseline, 0.5, 1,2,3 months No
Secondary Cytokines IL-1a, IL-1ß, IL-2, IL-4, IL-6, IL-10, IL-12(p70), IFN-?, TNF-a baseline, 0.5, 1,2,3 months No
Secondary Leptin baseline, 0.5, 1,2,3 months No
Secondary Adiponectin baseline, 0.5, 1,2,3 months No
Secondary Epinephrine baseline, 0.5, 1,2,3 months No
Secondary Norepinephrine baseline, 0.5, 1,2,3 months No
Secondary C reactive protein baseline, 0.5, 1,2,3 months No
Secondary BDNF serum, plasma, platelet BDNF baseline, 0.5, 1,2,3 months No
Secondary MINI plus structured interview assessing for DSM-IV Axis I disorders with strong reliability and validity in relation to the Structured Clinical Interview for DSM-IV (SCID-IV) Baseline No
Secondary MINI Suicidality Module assess current and past Axis I diagnoses baseline, 0.5, 1,2,3 months No
Secondary Hamilton Depression Rating Scale-17(HAMD-17) changes of HAMD-17 total socres baseline, 0.5, 1,2,3 months No
Secondary Hamilton Anxiety Rating Scale(HAMA) changes of HAMA total scores baseline, 0.5, 1,2,3 months No
Secondary Anxiety Sensitivity Index(ASI) ASI-3 to measure the three most supported AS domains: social (i.e., fear of exhibiting symptoms in public that may elicit embarrassment), cognitive (i.e., fear of losing cognitive control or experiencing concentration difficulties), and physical (i.e., fear that physical sensations are a sign of an immediate physical problem). baseline, 0.5, 1,2,3 months No
Secondary APPQ(Albany Panic and Phobia Questionnaire) The APPQ (Rapee et al., 1995) is a 27-item instrument that is designed to measure interoceptive, agoraphobic, and social situational fear. Subjects respond to each item on a 9-point Likert scale from 0 to 8, according to how much fear they think they would experience in a given situation so that total scores range from 0 to 216. baseline, 0.5, 1,2,3 months No
Secondary PSWQ(Penn state worry questionnaire) 16-item questionnaire that aims to measure the trait of worry, using Likert rating from 1 (not at all typical of me) to 5 (very typical of me) baseline, 0.5, 1,2,3 months No
Secondary SRI(Stress response Inventory) emotional, somatic, cognitive, and behavioral stress responses. baseline, 0.5, 1,2,3 months No
Secondary Perceived Stress Scale(PSS) The Perceived Stress Scale (PSS) is the most widely used psychological instrument for measuring the perception of stress. It is a measure of the degree to which situations in one's life are appraised as stressful. baseline, 0.5, 1,2,3 months No
Secondary Barratt Impulsivity Scale The Barratt Impulsiveness Scale (BIS) is a widely used measure of impulsiveness. It includes 30 items that are scored to yield six first-order factors (attention, motor, self-control, cognitive complexity, perseverance, and cognitive instability impulsiveness) and three second-order factors (attentional, motor, and non-planning impulsiveness).The BIS-11 is a 30-item self-report questionnaire, that is scored to yield a total score, three second-order factors, and six first-order factors. baseline, 0.5, 1,2,3 months No
Secondary Panic disorder severity scale(PDSS) The items assess panic frequency, distress during panic, panic-focused anticipatory anxiety, phobic avoidance of situations, phobic avoidance of physical sensations, impairment in work functioning, and impairment in social functioning. The overall assessment is made by a total score, which is calculated by summing the scores for all seven items. The total scores range from 0 to 28. baseline, 0.5, 1,2,3 months No